Comment on Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker

Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker

Chris Roop, head of M&A for the Americas at investment bank Jefferies, said Big Pharma will be looking for new drugs to boost growth in 2025.GP Kidd/Getty ImagesA top M&A banker said Big Pharma will be on the hunt for more acquisitions in 2025.Major drugs including Keytruda and Eliquis will see patent exclusivity expire in coming years.Pharma companies look at areas such as obesity to supplement growth, Jefferies' Chris Roop said.Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker.Merck's cancer drug Keytruda, the top-selling medication in the world, will lose patent exclusivity at the end of 2028.Eliquis, made by Pfizer and Bristol-Myers Squibb to treat and prevent blood clots, will lose its exclusivity earlier that same year.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News